Related Experiment Video

Updated: Aug 21, 2026

In Vivo Quantification of Hip Arthrokinematics during Dynamic Weight-bearing Activities using Dual Fluoroscopy
07:43

In Vivo Quantification of Hip Arthrokinematics during Dynamic Weight-bearing Activities using Dual Fluoroscopy

Published on: July 2, 2021

Fluoroquinolones in children: poorly defined risk of joint damage

    Prescrire International
    |October 27, 2004
    PubMed

    Insights

    Systemic fluoroquinolones can cause rare joint damage in children, often resolving after stopping the drug. Ciprofloxacin is preferred over pefloxacin due to a lower risk of this adverse effect.

    Area of Science:

    • Pediatric pharmacology
    • Drug safety
    • Rheumatology

    Background:

    • Systemic fluoroquinolones are sometimes used in pediatric patients.
    • Rare cases of joint damage have been reported in children treated with these antibiotics.
    • The exact incidence and causality of fluoroquinolone-associated joint damage in children are not fully established.

    Purpose of the Study:

    • To review the evidence regarding joint damage associated with systemic fluoroquinolone use in children.
    • To provide guidance on the appropriate use of fluoroquinolones in pediatric populations.
    • To compare the risk of joint damage between different fluoroquinolone agents.

    Main Methods:

    • Literature review of case reports and pediatric trials.
    • Analysis of reported adverse events related to fluoroquinolone therapy in children.
    • Comparative assessment of drug-specific risks.

    Main Results:

    • Joint damage is a rare but documented adverse effect of systemic fluoroquinolones in children.
    • This joint damage typically resolves after drug discontinuation.
    • Pefloxacin appears to be associated with a higher frequency of joint damage compared to other fluoroquinolones.

    Conclusions:

    • Fluoroquinolone use in children should be reserved for situations where benefits clearly outweigh the risks.
    • Ciprofloxacin is recommended as the first-line fluoroquinolone in pediatric cases where therapy is indicated.
    • Pefloxacin should be avoided in pediatric treatment due to increased risk of joint toxicity.

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Drug Toxicity: Risk factors01:24

    Drug Toxicity: Risk factors

    Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...